Ovid falls on Phase II data for Angelman syndrome candidate

Ovid Therapeutics Inc. (NASDAQ:OVID) fell $3.44 (36%) to $6.08 on Monday after reporting that gaboxadol (OV101) failed to significantly improve prespecified efficacy measures of behavior, sleep and gait in the Phase II STARS trial to treat Angelman syndrome. The company said one dose

Read the full 430 word article

User Sign In